EUVIMEDEUVIMED entdecken
Crossref

Synergistic CHA and CRISPR/Cas12a Amplification−Enhanced SERS Biosensor for Sensitive ctDNA Detection in Lung Cancer

Yongshi Shen, Luyun Xu, Yuanmei Chen, Chaobin Huang, Zhizhong Lin, Shangyuan Feng, Jinyong Lin, Yuanji Xu

Analytical Chemistry · 22.11.2026

DOI: 10.1021/acs.analchem.6c05427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 22.11.2026. Verfasst von Yongshi Shen und 7 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Fujian Provincial Department of Science and Technology, Fuzhou Science and Technology Bureau, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A surface-enhanced Raman scattering (SERS) biochip integrating CRISPR/Cas12a with catalytic hairpin assembly (CHA) was developed for the ultrasensitive and precise quantification of circulating tumour DNA (ctDNA) harbouring non-small-cell lung cancer (NSCLC) associated mutations. Upon hybridization with target ctDNA, the CHA circuit generates abundant H1−H2 duplexes, which efficiently activate the trans-cleavage activity of Cas12a. The activated Cas12a indiscriminately cleaves linker single-stranded DNA (ssDNA), thereby disrupting the programmed self-assembly of SERS nanoprobes (Au@MBN@Ag NPs) on a two-dimensional Ag-coated silicon substrate. This disruption reduces local electromagnetic “hot spots”, producing a ratiometric SERS signal inversely proportional to ctDNA concentration. The intrinsic silicon Raman band at 520 cm−1 was used as an internal reference, reducing measurement variability and improving the reproducibility of the ratiometric SERS response under the investigated conditions. Under the investigated conditions, the estimated limits of detection were calculated to be 24.06 aM for EGFR L858R and 15.6 aM for EGFR Del19 based on the corresponding calibration models. The biosensor exhibited sequence-dependent responses and limited interference from the tested non-target DNA sequences. In a preliminary clinical evaluation involving 23 serum samples, the biosensor showed concordant EGFR mutation classifications with the corresponding tissue biopsy and NGS findings. Although these results support the feasibility of the proposed strategy for ctDNA analysis, further validation in larger and independent clinical cohorts is required to establish its diagnostic performance and clinical utility.

Förderung

  • Fujian Provincial Department of Science and Technology
  • Fuzhou Science and Technology Bureau
  • National Natural Science Foundation of China
  • Quanzhou High-Level Talent Innovation and Entrepreneurship Project

Zitieren

APA

Shen, Y., Xu, L., Chen, Y., Huang, C., Lin, Z., Feng, S., Lin, J., & Xu, Y. (2026). Synergistic CHA and CRISPR/Cas12a Amplification−Enhanced SERS Biosensor for Sensitive ctDNA Detection in Lung Cancer. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.6c05427

Vancouver

Shen Y, Xu L, Chen Y, Huang C, Lin Z, Feng S, et al. Synergistic CHA and CRISPR/Cas12a Amplification−Enhanced SERS Biosensor for Sensitive ctDNA Detection in Lung Cancer. Analytical Chemistry. 2026. doi:10.1021/acs.analchem.6c05427

BibTeX
@article{Shen2026,
  author = {Shen, Yongshi and Xu, Luyun and Chen, Yuanmei and Huang, Chaobin and Lin, Zhizhong and Feng, Shangyuan and Lin, Jinyong and Xu, Yuanji},
  title = {Synergistic CHA and CRISPR/Cas12a Amplification−Enhanced SERS Biosensor for Sensitive ctDNA Detection in Lung Cancer},
  journal = {Analytical Chemistry},
  year = {2026},
  doi = {10.1021/acs.analchem.6c05427}
}
Kostenlos starten →